Brief: ASIT Biotech Announces Publication of Study of Lead Product For Grass Pollen Allergy
March 5 (Reuters) - ASIT BIOTECH SA ASIT.BR :
* ASIT BIOTECH REVEALS THE MODE OF ACTION OF ITS LEAD
IMMUNOTHERAPY PRODUCT FOR ALLERGIC RHINITIS, GP-ASIT+™, IN THE
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (JACI)
Source text for Eikon: urn:newsml:reuters.com:*:nBw2fxQVfa
Further company coverage: ASIT.BR
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on European Medical Solutions SA
See all newsBrief: DMS Imaging H1 EBITDA Rises To EUR 2.2 Million
Brief: DMS Imaging Announces Resumption Of Project To Transfer Its Listing Securities On Euronext Growth Market In Paris And Brussels
Brief: DMS Imagining Announces End Of Litigation With Thierry Legon
Brief: DMS Imaging Sees 2023 Revenue At 40 Million Euros
Brief: DMS Imaging Says Fujifilm Healthcare Italy Wins Tender For Its Radiology Tables